[Doxazosin, of modified liberation, in hemodialyzed patients].
BACKGROUND
Valuation of doxazosin, system formulation modified, in the hypertension in the hemodialysis population.


METHODS
Arterial Hypertension (AHT) has been studied in 77 patients (p) subjected to hemodialysis (HD). Mean age (mag) was 61 years (y), range 84y-25y; 66% were males. The underlying etiology was glomerular in 19%, tubulo-interstitial in 18%, congenital in 18%, vascular in 19% and diabetic in 26%.


RESULTS
Doxazosin (system formulation modified, single daily dose (4 mg), treatment follow-up was completed in 16 patients subjected to HD for 24 weeks (wk).


CONCLUSIONS
It is concluded that AHT is of great importance in HD, and can be adequately controlled with the new antihypertensive drugs. In this context, doxazosin affords excellent therapeutic control, efficiency and good pharmacological tolerance.
Ocharán-Corcuera
J
J
Servicio de Nefrología, Hospital de Galdakao, Bizkaia.
Iribar
I
I
Saracho
R
R
Martínez
I
I
Montenegro
J
J
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D017292:Doxazosin / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis
D000959:Antihypertensive Agents; D017292:Doxazosin